People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $86.5M | $1.1B | 2015 |
| SteadyMed Ltd. | — | Pharmaceuticals | Series B | $51.3M | $1.0B | 2016 |
| Sernova Corp. | — | Biotechnology | Pre-Seed | $573K | $2.0M | 2024 |
| Sernova Biotherapeutics Inc. | — | Biotechnology | Pre-Seed | $345K | $694K | 2025 |
Jonathan Rigby at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Rigby on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JAMES PARSONS | 2 | 6 |
| Bernd Muehlenweg | 2 | 2 |
| Timothy Sullivan | 1 | 16 |
| John Brooks | 1 | 8 |
| Navneet Puri | 1 | 3 |
| Douglas Baum | 1 | 3 |
| DAVID BURKE | 1 | 3 |
| Phillip Johnson | 1 | 2 |
| David W. Nassif | 1 | 2 |
| John Shannon | 1 | 2 |
| Jeffrey A. Bacha | 1 | 2 |
| Frank A. Holler | 1 | 2 |
| James T. Parsons | 1 | 2 |
| Cary McNair | 1 | 1 |
| Doug Baum | 1 | 1 |
| Robert Faulker | 1 | 1 |
| John Kinzel | 1 | 1 |
| Ron W. Ginor | 1 | 1 |
| Shane Brisbin | 1 | 1 |
| Donald W. Huffman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.